Affiliation:
1. Department of Chemistry GITAM School of Science (Deemed To Be University) Hyderabad Telangana India
2. Department of Analytical Research and Development Graviti Pharmaceuticals Private Limited Isnapur Telangana India
3. Department of Analytical Research and Development Amneal Pharmaceuticals Piscataway New Jersey USA
4. Department of Research & Development and Quality Operations InvaHealth Inc. Cranbury New Jersey USA
Abstract
AbstractPropranolol hydrochloride (PPH) is a medication of beta‐adrenergic receptors. It is used to treat pediatric hemangiomas that are growing and need systemic therapy. A reversed‐phase high‐performance liquid chromatography (HPLC) was made to separate and estimate the amounts of ten known organic impurities of propranolol in bulk drugs, tablets, and capsule dosage forms. The chromatographic separation was achieved on a C18 column (100 × 4.6 mm, 2.7 μm) using a binary gradient mixture of pH 2.3 phosphate buffer and organic modifiers of acetonitrile, methanol, and isopropyl alcohol as the mobile phase. The stability‐indicating character of the proposed method was proven using stress testing study. The test method was validated for specificity, limit of detection, limit of quantitation, linearity, precision, accuracy, and robustness. For the propranolol and its ten organic impurities, the limit of quantitation, linearity, and recoveries were found in a range of 0.0123–0.4266 μg/mL (R2 > 0.9982) and 89.2–98.9%, respectively. The proposed liquid chromatography method is found to be highly suitable for impurity profiling of propranolol in bulk drugs and pharmaceutical formulations (tablets and capsules).
Subject
Filtration and Separation,Analytical Chemistry
Reference29 articles.
1. Inderal®. (Propranolol hydrochloride Tablets) (Accessed June 20 2023).https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080 016762s017 017683s008lbl.pdf
2. HEMANGEOL®. (Propranolol hydrochloride) oral solution Initial U.S. Approval: 1967. (Accessed June 20 2023).https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205410s005lbl.pdf
3. Molecular docking, in-vitro anticancer evaluation and ADME profiling of 7-Oxo Midostaurin
4. ICH.Q3A(R2): Impurities in new drug substances. Current step 4 version dated 25 October 2006. Accessed June 20.2023.https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf
5. ICH.Q3B(R2): Impurities in new drug products. Current step 4 version dated 2 June 2006. Accessed on June 20 2023.https://database.ich.org/sites/default/files/Q3B%28R2%29%20Guideline.pdf